UBS Group
CYTK icon

UBS Group’s Cytokinetics CYTK Stock Holding History

UBS Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,800
Closed -$1.07M – 9419
2023
Q4 		$1.07M Sell
12,800
-78,500
-86% -$2.84M ﹤0.01% 4438
2023
Q3 		$2.69M Buy
91,300
+74,700
+450% +$2.49M ﹤0.01% 3158
2023
Q2 		$541K Hold
16,600
– – ﹤0.01% 4753
2023
Q1 		$584K Buy
+16,600
New +$677K ﹤0.01% 4569

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group's CYTK Position: Q1 2026 in Review

UBS Group increased its Cytokinetics (CYTK) stake by 84% in Q1 2026, buying an estimated $60.1M and bringing the position to 2,077,277 shares worth $137M. The position accounts for 0.02% of the portfolio, ranked #822.

UBS Group first reported a position in CYTK in Q4 2014 and has held it in 46 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • UBS Group held 2,077,277 shares of Cytokinetics worth $137M as of Q1 2026.
  • UBS Group bought 945,821 Cytokinetics shares in Q1 2026, an estimated $60.1M.
  • Cytokinetics made up 0.02% of UBS Group's portfolio in Q1 2026, its #822 holding.
  • UBS Group first reported a position in Cytokinetics in Q4 2014 and has held it in 46 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.